Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
Lysando AGLysando AG is a biopharmaceutical company specialized in antimicrobial protein technologies for combating pathogenic bacteria, particularly resistant and persistent strains. With a core focus on addressing antimicrobial resistance while preserving the human microbiome, the company develops protein-based therapeutic platforms for wound care, dermatology, and broader bacterial infection control. Lysando's solutions aim for effective pathogen management with low risk of resistance development, supporting sustainability and patient-centered healthcare outcomes.
Lysando AG is a biopharmaceutical company specialized in antimicrobial protein technologies for combating pathogenic bacteria, particularly resistant and persistent strains. With a core focus on addressing antimicrobial resistance while preserving the human microbiome, the company develops protein-based therapeutic platforms for wound care, dermatology, and broader bacterial infection control. Lysando's solutions aim for effective pathogen management with low risk of resistance development, supporting sustainability and patient-centered healthcare outcomes.
Publication Number
US-10485854-B2
Publication Date
2019-11-26
Expiration Date
Abstract
The present invention relates to methods of eliminating, reducing or preventing bacterial biofilms by means of a fusion protein comprising an endolysin, an autolysin or a bacteriocin to which a peptide with membrane or LPS disrupting activity is fused. Further, the present invention relates to fusion proteins for use as a medicament, in particular for the treatment or prevention of Gram-negative and/or Gram-positive bacterial infections associated with bacterial biofilm, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative and/or Gram-positive bacterial contamination associated with bacterial biofilm of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to the use of said fusion protein as a diagnostic means in medicinal, food or feed or environmental diagnostic associated with bacterial biofilm.
Core Innovation
The described invention relates to fusion proteins and their use for eliminating or reducing bacterial biofilms. A fusion protein is provided in which a Gram-positive or Gram-negative cell-wall-degrading enzyme, including an endolysin, autolysin, or bacteriocin, is fused to a peptide having bacterial membrane disrupting activity and/or bacterial lipopolysaccharide (LPS) disrupting activity. The fusion protein is applied by contacting a material, liquid, surface, or biological material exhibiting biofilm with the fusion protein.
The invention addresses bacterial biofilms and extracellular polymeric substances (EPS), which confer antimicrobial resistance and reduce the effectiveness of antimicrobial agents. The fusion design enables the cell-wall-degrading enzyme to access and lyse biofilm-associated bacteria by using the peptide component to disrupt the outer membrane and/or LPS.
The disclosure includes defined peptide and enzyme combinations, including fusion of a polycationic peptide to an endolysin, and alternative fusion configurations with peptide fused N-terminally and/or C-terminally to the enzyme. Experimental examples described include fusion protein construction and expression, assays to evaluate antibacterial and antifouling effects, and discussion of peptide selections and enzyme-peptide fusion formats.
Claims Coverage
The provided claims center on a fusion protein architecture for eliminating or reducing a bacterial biofilm, with two inventive features combining an endolysin with a membrane-disrupting or LPS-disrupting peptide and contacting a biofilm-exhibiting target material or biological material.
Endolysin fused to membrane- or LPS-disrupting peptide
providing a fusion protein comprising an endolysin phiKZgpl44, SEQ ID NO: 1, to which a peptide SEQ.ID.NO: 100 with bacterial membrane disrupting activity or bacterial lipopolysaccharide (LPS) disrupting activity is fused
Contacting a biofilm-exhibiting material with the fusion protein
contacting a material, liquid, surface or biological material exhibiting said biofilm with said fusion protein, thereby eliminating or reducing the bacterial biofilm
Across the claim set provided, the core claimed concept is an endolysin fused to a peptide that disrupts bacterial membrane and/or LPS, applied by contacting biofilm-containing materials or biological material to eliminate or reduce the biofilm.
Stated Advantages
Eliminating or reducing a bacterial biofilm by contacting the biofilm with the fusion protein.
Improving antibacterial and antifouling performance in association with example fusion proteins, including elimination or reduction of biofilms in assays and improved activity against Gram-negative strains as reported in the disclosure.
Documented Applications
Use for eliminating or reducing bacterial biofilms on a material, liquid, surface, or biological material.
Use as a medicament, disinfectant, cosmetic, and diagnostic.
Removal of biofilm from food and from medical device and hospital surfaces.
Interested in licensing this patent?